Results 71 to 80 of about 7,987 (192)

Efficacy and Safety of Fruquintinib Plus TAS‐102 in Patients With Previously Treated Metastatic Colorectal Cancer: Results From a Single‐Arm, Multi‐Center, Phase II Study

MedComm, Volume 7, Issue 10, October 2026.
This study is the first prospective clinical trial that evaluated the efficacy and safety of fruquintinib combined with TAS‐102 in the later‐line treatment of patients with mCRC. Fruquintinib plus TAS‐102 demonstrated promising efficacy and manageable safety profile in patients with mCRC who had failed at least two standard therapies, supporting its ...
Jianjun Peng, Yong Li, Ling Huang, Jianhua Liu, Jianjun Xiao, Derong Xie, Wei Wang, Zongcheng Zhang, Chengyin Weng, Xiaoshu Chai, Huifen Li, Xiaomei Jiang, Yan Qian, Risheng Zhao, Sile Chen, Zhimin Jiang, Lingdan Le, Xueqin Li, Jianting Long, Haibo Zhang, Chuangqi Chen, Shirong Cai   +21 more
wiley   +1 more source

Assessing the effectiveness of camrelizumab plus apatinib versus sorafenib for the treatment of primary liver cancer: a single-center retrospective study

Scientific Reports, 2023
Although the effectiveness of camrelizumab plus apatinib has been confirmed in a phase II clinical study, the efficacy of camrelizumab plus apatinib versus sorafenib for primary liver cancer (PLC) remains unverified. We retrospectively collected the data
Dongbo Chen, Yichun Wang, Xiangxun Chen, Mei Kang, Liyang Zhu   +4 more
doaj   +1 more source

Sintilimab Combined With Albumin‐Bound Paclitaxel and SOX Regimen as Conversion Therapy for Unresectable Advanced Gastric Cancer Achieving Complete Remission: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT For carefully selected patients with unresectable advanced gastric cancer, immunochemotherapy combining PD‐1 inhibitor with albumin‐bound paclitaxel and S‐1/oxaliplatin may achieve deep remission and enable successful R0 resection. Our findings suggest that this multimodal conversion approach could be considered in selected cases with ...
Yufan Tang, Boquan Zhou, Bingbing Wen, Ke Yu, Jiajia Jia, Ying Sha, Jixiang Liu, Luyao Li, Ruifang Fan   +8 more
wiley   +1 more source

Apatinib as Salvage Therapy for Heavily Pretreated SCLC

, 2018
Small cell lung cancer (SCLC) was highly malignant and lack effective treatment after the failure of radiotherapy and chemotherapy. Antiangiogenic therapy had shown a certain effect in advanced SCLC.
Haitao TAO, Fangfang LI
core   +1 more source

Effect of Apatinib plus melatonin on vasculogenic mimicry formation by cancer stem cells from breast cancer cell line

, 2022
Background and aim: Vasculogenic mimicry (VM) is one of the most important causes of breast cancer metastasis and resistance against drugs. The cancer stem cells (CSCs) are known as essential factors for VM formation.
Vahedian, V., Jahanbazi, R., Nejabati, H. R., Maroufi, N. F., Rashidi, M., Kazemzadeh, H., Rashidi, M. R., Mostafaei, S., Isazadeh, A., Nouri, M., Akbarzadeh, M.   +10 more
core   +1 more source

Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions

Cancer Management and Research, 2019
Zhichao Tian,1 Xin Wang,1 Zhiyong Liu,1 Jiaqiang Wang,1 Weitao Yao,1 Yao Zhao,2 Songtao Gao,3 Peng Zhang,1 Hong Ge41Department of Orthopedics, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, Henan Province, People’s ...
Tian Z, Wang X, Liu Z, Wang J, Yao W, Zhao Y, Gao S, Zhang P, Ge H   +8 more
doaj  

Apatinib is effective for treatment of advanced hepatocellular carcinoma [PDF]

Oncotarget, 2017
As treatment options for hepatocellular carcinoma (HCC) are currently limited, we evaluated the efficacy and safety of oral apatinib, a VEGFR-2 inhibitor, on patients with advanced HCC. Twenty-two patients from Tianjin Medical University Cancer Institute and Hospital were enrolled for evaluation.
Kong, Yinlong, Sun, Lin, Hou, Zhenyu, Zhang, Yongqiang, Chen, Ping, Cui, Yunlong, Zhu, Xiaolin, Song, Tianqiang, Li, Qiang, Li, Huikai, Zhang, Ti, Qin, Lunxiu   +11 more
openaire   +2 more sources

Immune Checkpoint Inhibitors in Cancer Therapy: Clinical Landscape, Resistance Mechanisms, and Therapeutic Innovations

MedComm – Oncology, Volume 5, Issue 3, September 2026.
The up‐to‐date clinical progress of immune checkpoint inhibitor (ICI) therapy in solid tumors, specifically the combinational regimens between ICIs and other treatment strategies, the mechanisms underlying primary and acquired resistance, and mechanism‐matched strategies to improve clinical outcomes are synthesized in this review.
Qiongyu Zhang, Zhi Qin, Caijuan Guo
wiley   +1 more source

Metabolism and Pharmacokinetics of Novel Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor Apatinib in Humans [PDF]

, 2020
Apatinib is a new oral antiangiogenic molecule that inhibits vascular endothelial growth factor receptor-2. The present study aimed to determine the metabolism, pharmacokinetics, and excretion of apatinib in humans and to identify the enzymes responsible
Juefang Ding, Lijia Zhang, Haoyuan Jiang, Zhiwei Gao, Xiaoyan Chen, Dafang Zhong, Cen Xie, Xiaojian Dai, Liang Li   +8 more
core  

Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia

Journal of Translational Medicine, 2018
Background Acute lymphoblastic leukemia (ALL) is a clonal malignant disorder characterized by an uncontrolled proliferation of immature B or T lymphocytes.
Manman Deng, Jie Zha, Zhiwu Jiang, Xian Jia, Yuanfei Shi, Peng Li, Xiao Lei Chen, Zhihong Fang, Zhiqiang Du, Bing Xu   +9 more
doaj   +1 more source